PharmaBiome AG, a pioneer in next-generation microbiome therapies recently extended its recent capital increase to a total of CHF 2.15 million. The proceeds will support the advancement of their lead product towards clinical trials in ulcerative colitis.
PharmaBiome also welcomed two new board members with extensive biotech and entrepreneurial experience, all the way from founding to IPO. Dr. Thomas Meier joins PharmaBiome as its new chairman with a strong track record as founder and CSO in pharma including Santhera, which he most recently led as its CEO. Dr. Patrick Forrer joins as Board member with strong founding and strategic experience at both Molecular Partners AG and Athebio AG. Thomas and Patrick will both support PharmaBiome’s growth towards clinical validation and the strengthening of its unique platform technology.
You can download the full press release here
